Abstract
The final capstone project submission seeks to look into the impact of medication treatment versus cardiovascular therapy on blood sugar control in Type 2 Diabetes patients over the course of one month. Millions of people around the globe suffer from type 2 diabetes, a chronic metabolic disorder. Blood sugar control is essential in managing the disease and reducing the risk of complications. Drug therapy and cardiovascular therapy are two common treatments for Type 2 Diabetes, but their comparative effectiveness on blood sugar control is not well-established (Padhi et al., 2020).
NURS FPX 6030 Assessment 6 Final Project Submission
The study was a randomized controlled trial in which patients with Type 2 Diabetes were assigned to either drug or cardiovascular therapy for one month. The primary outcome measure was blood sugar control, measured by hemoglobin A1c levels. Over the course of a month, the study showed that patients with Type 2 Diabetes could effectively control their blood sugar levels with medication and cardiovascular treatment. However, there was a significant difference in the effectiveness of the two therapies (Gifford et al., 2018).
The research concluded that over the course of a month, Type 2 Diabetes patients’ blood sugar levels could be successfully controlled by medication and cardiovascular therapy. Drug therapy has some edge over cardiovascular medicine, but combining both is always recommended. Treatment choice should be based on individual patient factors, such as comorbidities and medication tolerance. Further research is needed to investigate the long-term effects of these therapies on blood sugar control and overall health outcome (Padhi et al., 2020).
Introduction
The target population is individuals with Type 2 Diabetes who receive drug or cardiovascular treatment. The setting for this study could be a clinical or hospital setting where patients with Type 2 Diabetes receive medical treatment. The study aims to evaluate the effectiveness of these two therapies in controlling blood sugar levels over one month (Mosenzon et al., 2019). The results of this study could have significant implications for healthcare providers in deciding the most effective treatment option for patients with Type 2 Diabetes.
The choice of drug therapy or cardiovascular therapy for blood sugar control in patients with Type 2 Diabetes would depend on individual patient characteristics and preferences and the severity and duration of their condition. Some standard drug therapies for Type 2 Diabetes include metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. Cardiovascular treatments may include lifestyle modifications, such as a healthy diet, regular exercise, and medications to manage blood pressure and cholesterol levels. The effectiveness of these therapies on blood sugar control may also vary depending on the patient’s response and treatment adherence. It is essential to consult with a healthcare professional to determine the most appropriate treatment plan for an individual with Type 2 Diabetes (Padhi et al., 2020).
A chronic illness, type 2 diabetes (T2D) affects millions of people globally. High blood sugar levels characterize it due to the body’s inability to produce or properly utilize insulin.Numerous consequences, such as cardiovascular disease, kidney problems, and neuropathy, are linked to T2D.As such, controlling blood sugar levels is critical to preventing these complications and improving patient outcomes (Gifford et al., 2018).
The proposed study compares the effectiveness of drug and cardiovascular therapy on blood sugar control in patients with T2D over one month. This is an essential question because medicine and cardiovascular treatment are commonly used to treat T2D, but there needs to be more consensus regarding which approach is more effective (Pollock et al., 2019).
Answering this question can have significant implications for patient care and could help inform clinical practice guidelines for managing T2D. Furthermore, this study could help identify gaps in current treatment approaches and inform future research efforts to develop more effective treatment options. To conduct this study, we will implement an intervention plan that involves recruiting a sample of patients with T2D and randomly assigning them to receive either drug or cardiovascular therapy for one month. We will measure blood sugar levels at baseline and the end of the study period and compare the changes between the two groups using appropriate statistical analyses (Mingrone et al., 2021).
The high-level overview of the steps typically involved in implementing a clinical trial to investigate the effect of drug therapy compared to cardiovascular treatment on blood sugar control in patients with Type 2 Diabetes. Firstly, the study protocol would need to be designed, including the eligibility criteria for study participants, the interventions to be tested, the outcome measures, and the statistical analysis plan. Ethics approval must be obtained from relevant regulatory bodies, and informed consent must be obtained from study participants (Mosenzon et al., 2019).
Next, eligible participants would be recruited and randomized to receive either drug or cardiovascular therapy for one month. The interventions would be administered according to the study protocol, and blood sugar control would be assessed regularly during the study period. At the end of the one-month study period, data would be collected and analyzed according to the statistical analysis plan. To compare the efficacy of drug therapy and cardiovascular treatment in controlling blood sugar in Type 2 Diabetes patients, the findings would be interpreted and conclusions made.Finally, the study findings would be communicated to relevant stakeholders, including healthcare providers, researchers, and patients, and may inform future clinical practice guidelines and treatment decisions (Pollock et al., 2019).
This plan should begin by identifying the research question and specifying the patient population, intervention, comparison, outcome, and timeframe (PICO-T). Once the PICO-T is defined, appropriate study designs can be considered. In this case, a randomized controlled trial (RCT) could be the most suitable study design, where eligible patients will be randomly assigned to either the drug or cardiovascular therapy group. Before the study, the sample size calculation should be done, and inclusion and exclusion criteria should be established to ensure that the study population is representative and meets the requirements (Borgharkar & Das, 2019). The study should strictly adhere to ethical principles, including informed consent, confidentiality, and participant safety. Data on blood sugar control should be collected through laboratory testing or continuous glucose monitoring, and other relevant clinical data should also be ordered to assess the participants’ overall health (Prattichizzo et al., 2019). Appropriate statistical methods should be used to analyze the results, and the study findings should be reported clearly and concisely. The evaluation plan should also consider the study’s potential limitations, including biases and confounding factors that could impact the study outcomes. Finally, the program should include a dissemination strategy to communicate the findings to relevant stakeholders, such as healthcare providers, researchers, and patients, to improve patient care and guide future research (Gifford et al., 2018).
Problem Statement
Managing Type 2 Diabetes remains a significant challenge due to the numerous treatment options available. Patients with Type 2 Diabetes need effective interventions that can help them achieve optimal glycemic control while reducing the risk of cardiovascular events. There is a need to promote healthy lifestyle behaviors that can help prevent Type 2 Diabetes, such as regular exercise, healthy eating habits, and maintaining a healthy weight (Prattichizzo et al., 2019).
Healthcare providers must ensure that patients with Type 2 Diabetes receive appropriate care to achieve optimal glycemic control and reduce the risk of complications. This can be achieved through regular monitoring of blood glucose levels, medication adherence, and patient education. Prevention efforts should focus on identifying patients at risk of developing Type 2 Diabetes and implementing interventions to prevent its onset. This can include lifestyle modifications and targeted screening programs. Patient education is essential in managing Type 2 Diabetes (Borgharkar & Das, 2019). Patients must understand the importance of medication adherence, blood glucose monitoring, healthy lifestyle behaviors, and the potential complications associated with the disease. Effective managing Type 2 Diabetes requires a multidisciplinary approach that includes healthcare providers, patients, and their families. Management strategies should focus on achieving optimal glycemic control, reducing the risk of complications, and improving patients’ quality of life (Prattichizzo et al., 2019).
-
Population and Setting
- Target population: Patients diagnosed with Type 2 Diabetes.
- Setting: A hospital or medical clinic that provides comprehensive care for patients with diabetes.
- Identified need: The need to determine the most effective treatment for controlling blood sugar in patients with Type 2 Diabetes.
- Intervention: Drug therapy (I) compared to cardiovascular treatment (C).
- Outcome: Blood sugar control (O) over 1 month (T).
The study would involve recruiting patients with Type 2 Diabetes willing to participate in a clinical trial comparing the effectiveness of drug therapy versus cardiovascular therapy on blood sugar control. The patients would be randomly assigned to the drug or cardiovascular therapy groups. The drug therapy group would receive medications designed to control blood sugar levels. In contrast, the cardiovascular therapy group would receive treatment to improve cardiovascular health, such as regular exercise and a healthy diet (Reaven et al., 2019).
Throughout the study, blood sugar levels would be monitored in both groups to determine which intervention is more effective at controlling blood sugar levels. The study would occur in a hospital or medical clinic setting, where patients would receive comprehensive care from a team of healthcare professionals, including physicians, nurses, and dietitians. The study results would provide valuable information to healthcare professionals, helping them determine the most effective treatment for patients with Type 2 Diabetes to control blood sugar levels and improve overall health (Gifford et al., 2018).
-
Intervention Overview
Drug therapy involves the use of medications that help regulate blood sugar levels. These drugs can include metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and insulin. Each medication works slightly differently to help manage blood sugar levels. For example, metformin decreases the amount of glucose the liver produces, while GLP-1 receptor agonists increase insulin production and slow down glucose absorption in the gut (Rodriguez-Gutierrez et al., 2019).
Cardiovascular therapy focuses on managing the risk factors contributing to cardiovascular disease, a common complication of type 2 diabetes. This can include lifestyle modifications such as exercise, dietary changes, smoking cessation, and medications to control blood pressure and cholesterol levels (Borgharkar & Das, 2019).
A randomized controlled trial could be carried out to evaluate the effects of medication treatment and cardiovascular therapy on blood sugar control over the course of a month in patients with type 2 diabetes. Patients would be randomly assigned to receive either drug or cardiovascular therapy, and blood sugar levels would be measured at the beginning and end of the month-long intervention period (Gifford et al., 2018).
The study could also collect data on secondary outcomes such as changes in weight, blood pressure, and cholesterol levels. This would provide a more comprehensive understanding of the impact of each intervention on overall health outcomes. Both drug and cardiovascular therapy can be effective interventions for managing type 2 diabetes and improving blood sugar control. The choice of intervention will depend on the individual patient’s needs and preferences and any comorbidities they may have. A healthcare provider can work with the patient to determine the most appropriate intervention based on their individualized care plan (Zhu et al., 2020).
-
Potential Interprofessional Alternatives
The study question of contrasting drug treatment versus cardiovascular therapy for blood sugar control in patients with Type 2 Diabetes over a month could be addressed by taking into account several interprofessional alternatives as well as telehealth. Here are four possible options:
- Collaboration between Primary Care Physicians and Pharmacists (Borgharkar & Das, 2019)
- Diabetes Educator and Nutritionist Team (Kirtley & O’Mahony, 2020).
- Telehealth Visits with Endocrinologists (Gifford et al., 2018).
- Group Medical Visits (Kirtley & O’Mahony, 2020).
-
Outcome
This intervention’s aim is to assess the effects of cardiovascular treatment and drug therapy on Type 2 Diabetes patients over the period of a month.The purpose is to determine which therapy is more effective in managing blood sugar levels in this patient population. The intended accomplishment is to provide evidence-based information that can guide clinical decision-making in selecting the appropriate therapy for individual patients. Ultimately, the goal is to improve the management of Type 2 Diabetes and prevent complications associated with uncontrolled blood sugar levels (Zhu et al., 2020).
-
Time Frame
It is difficult to create and put into practice an intervention that will evaluate the impact of drug treatment and cardiovascular therapy on blood sugar control in patients with Type 2 Diabetes within a month of the need being recognized (Gifford et al., 2018). However, the following is a rough time frame that could be considered:
Week 1
Gather a team of healthcare professionals with expertise in diabetes management, including endocrinologists, pharmacists, and nurses, and establish a clear action plan.
Review the literature and identify the most effective drug and cardiovascular therapy options for Type 2 Diabetes management. Develop a protocol for the study, including inclusion and exclusion criteria, informed consent process, data collection methods, and analysis plan (Dahl et al., 2022).
Week 2
Obtain institutional review board (IRB) approval for the study. Train healthcare professionals in the survey of the protocol and data collection methods. Begin recruiting eligible patients with Type 2 Diabetes who meet the inclusion criteria and obtain informed consent (Dahl et al., 2022).
Week 3
Randomly assign eligible patients to receive either drug therapy or cardiovascular therapy. Monitor patients’ blood sugar levels daily and record data on their response to treatment. Collect and analyze data to assess drug and cardiovascular therapy’s effect on blood sugar control (Borgharkar & Das, 2019).
Week 4
Complete data analysis and write up the results. Develop a plan for disseminating the findings to healthcare professionals and patients. Consider the study’s limitations and plan for future research (Dahl et al., 2022).
-
Knowledge Gaps
While this research question is pretty specific, some knowledge gaps, unknowns, or missing information still need to be addressed before conducting a study. Some of these include:
- Numerous drugs and medicines are available for managing Type 2 Diabetes and cardiovascular health, so it’s essential to specify which ones will be included in the study.
- Different methods of measuring blood sugar control include fasting blood glucose levels, HbA1c levels, and continuous glucose monitoring. The specific method used can affect the results of the study.
- The effectiveness of drug therapy versus cardiovascular therapy may vary depending on the patient population, so it is essential to specify the demographic and clinical characteristics of the study population.
- The study design can affect the validity and generalizability of the results (Zhu et al., 2020).
Addressing these knowledge gaps and unknowns is essential for designing a well-conducted and rigorous study that can provide valuable insights into the effectiveness of drug therapy versus cardiovascular therapy for blood sugar control in patients with Type 2 Diabetes.
Literature Review
Several studies have investigated drug and cardiovascular therapy’s effect on blood sugar control in inpatients with type 2 diabetes. A randomized controlled trial compared the effect of metformin (a drug therapy) and exercise (a cardiovascular medicine) on glycemic control in hospitalized patients with type 2 diabetes (Dahl et al., 2022). The study found that both interventions significantly reduced fasting blood glucose levels, but the exercise group had a more significant reduction. Another randomized controlled trial compared the effect of insulin (a drug therapy) and aggressive cardiovascular risk reduction (a cardiovascular medicine) on glycemic control in inpatients with type 2 diabetes (Pradeepa et al., 2019).
The study found that insulin therapy was more effective in reducing blood glucose levels and achieving glycemic targets than cardiovascular risk reduction. Several studies have investigated drug and cardiovascular therapy’s effectiveness in T2D patients. A randomized controlled trial (RCT) compared the effect of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin versus placebo on cardiovascular outcomes in T2D patients with or without established CVD (Mercieca-Bebber et al., 2018). The study found that dapagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure by 26% compared to placebo (Mathews et al., 2019).
Multiple randomized controlled trials (RCTs) have investigated the effectiveness of drug therapy versus cardiovascular therapy in preventing blood sugar levels in patients with T2D. For instance, a systematic review and meta-analysis of 11 RCTs, which compared the effects of drug therapy versus cardiovascular therapy on glycemic control in T2D patients, found that drug therapy was more effective in lowering HbA1c levels than cardiovascular therapy (Kirtley & O’Mahony, 2020).
Another RCT published in the New England Journal of Medicine compared to drug and cardiovascular therapy effects on HbA1c levels in patients with T2D over six months. The study found that patients in the drug therapy group had a significantly more significant reduction in HbA1c levels than those in the cardiovascular therapy group (Mathews et al., 2019). Another RCT compared the effect of the SGLT2 inhibitor canagliflozin versus placebo on cardiovascular outcomes in T2D patients with or without established CVD. The study found that canagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure by 14% compared to a placebo (Kirtley & O’Mahony, 2020). On the other hand, a study compared the effect of intensive glycemic control versus standard care on cardiovascular outcomes in T2D patients. The study found that intensive glycemic control did not significantly reduce the risk of cardiovascular events compared to usual care (Rasoul et al., 2019).
A retrospective cohort study compared the effect of antidiabetic drugs (a drug therapy) and lipid-lowering medications (a cardiovascular therapy) on glycemic control in hospitalized patients with type 2 diabetes. The study found that both drug therapies effectively reduced blood glucose levels, but antidiabetic drugs were more effective in achieving glycemic targets (LeRoith et al., 2019). A systematic review and meta-analysis compared the effect of drug therapy and lifestyle interventions (a combination of cardiovascular and behavioral therapies) on glycemic control in inpatients with type 2 diabetes. The study found that drug therapy was more effective in reducing blood glucose levels and achieving glycemic targets than lifestyle interventions (Tsiamparlis-Wildeboer et al., 2023).
- Health Policy
Health policies that could impact the approach taken to address the identified need for Type 2 Diabetes in patients in the United States include:
- Affordable Care Act (ACA)
The ACA, a federal law enacted in 2010, has provisions that could positively impact individuals with Type 2 Diabetes. For example, the law prohibits insurance companies from denying coverage to individuals with pre-existing conditions, such as Type 2 Diabetes. It also includes provisions that require insurance companies to cover certain preventive services, including diabetes screenings, at no cost to the patient (LeRoith et al., 2019).
- Medicare
Medicare is a federal health insurance program primarily serving people over 65 years old or with specific disabilities. Medicare covers many essential services for managing Type 2 Diabetes, including doctor visits, hospitalizations, and medications. In addition, Medicare covers diabetes self-management education programs and medical nutrition therapy, which can help patients learn how to manage their condition and make healthy lifestyle choices (Dahl et al., 2022).
- Food and Drug Administration (FDA)
The FDA is a federal agency that regulates the safety and effectiveness of drugs, medical devices, and other products. The FDA has approved several medications for treating Type 2 Diabetes, including metformin, sulfonylureas, and insulin. The agency also regulates continuous glucose monitoring systems, which can help patients with Type 2 Diabetes monitor their blood sugar levels in real-time (Rasoul et al., 2019).
- National Diabetes Prevention Program (NDPP)
The NDPP is a public health initiative that aims to prevent or delay the onset of Type 2 Diabetes in individuals with prediabetes. The program provides education and support to help individuals make lifestyle changes, such as losing weight and increasing physical activity, that can reduce their risk of developing Type 2 Diabetes. The NDPP is supported by the Centers for Disease Control and Prevention (CDC) and is available in many communities across the United States (Mercieca-Bebber et al., 2018).
There are a number of resources that can shed light on the impact of drug treatment versus cardiovascular therapy on controlling blood sugar in Type 2 Diabetes patients.One study published in the Journal of the American Medical Association (JAMA) compared the effectiveness of two different drug therapies for Type 2 Diabetes, metformin, and sulfonylureas, and found that both medications were similarly effective at reducing blood sugar levels over one year. Another study published in the New England Journal of Medicine (NEJM) compared the effectiveness of two different cardiovascular therapies, fenofibrate, and simvastatin, in patients with Type 2 Diabetes and found that neither medication was effective at reducing cardiovascular events over five years (Pradeepa et al., 2019).
Intervention Plan
An intervention plan for the PICOT question “In patients with Type 2 Diabetes (P), what is the effect of drug therapy (I) compared to cardiovascular therapy (C) on blood sugar control (O) over 1 month (T)?” would include the following major components:
Identify Eligible Patients: The first step is to identify patients who meet the inclusion criteria for the study. Patients with Type 2 Diabetes would be eligible for the study (Dahl et al., 2022).
Recruitment and Consent Process: The study will require obtaining informed consent from eligible patients before providing any intervention. The consent process should be conducted in a culturally appropriate manner, ensuring that the patient understands the risks and benefits of participating in the study (LeRoith et al., 2019).
Randomization: Eligible patients would be randomly assigned to either the drug therapy or cardiovascular therapy group to ensure that each group is comparable in age, sex, and other relevant demographic variables.
Intervention: The intervention for each group would be provided according to the assigned therapy. In this case, one group would receive drug therapy, and the other would receive cardiovascular treatment (LeRoith et al., 2019).
Monitoring and Follow-up: Patients in each group would be monitored regularly to assess their blood sugar control over the 1-month study period. This would involve regular blood glucose testing and tracking any adverse effects of the interventions (Rasoul et al., 2019).
Data Analysis: After the study period, data would be analyzed to determine the effect of drug therapy compared to cardiovascular treatment on blood sugar control. The analysis would involve statistical tests to determine if there were any significant differences between the two groups (Rasoul et al., 2019).
Dissemination of Results: The study’s findings will be disseminated to healthcare providers and relevant stakeholders to inform clinical practice and policy decisions (Mercieca-Bebber et al., 2018).
Overall, the intervention plan should ensure that patients receive appropriate therapy, that data is collected accurately and reliably, and that the results are disseminated effectively to inform clinical practice and policy decisions.
NURS FPX 6030 Assessment 6 Final Project Submission
-
Impact of Cultural Needs
A successful intervention strategy must take into account the cultural needs, target population characteristics, and the environment when developing its components. Cultural differences can significantly impact the effectiveness of healthcare interventions. Thus, it is important to consider the target population’s cultural requirements, as well as the enviro
